Drug news
NICE recommends use of Opdivo in squamous non-small-cell lung cancer.- BMS.
Opdivo (nivolumab), from BMS, is recommended by NICE for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy, only if: nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and the conditions in the managed access agreement are followed.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.